With an eye to preparing for potential threats, the FDA has granted approval for the first live, non-replicating vaccine to prevent smallpox and monkeypox. Developed by Bavarian Nordic A/S and branded as Jynneos, after a priority review it was approved for prevention of the diseases in adults determined to be at high risk for the viral infections.